Genmab — April 2019
-
Det er alt for tidligt at dømme Maia ude af RTOR. FDA's tidsplan er vejledende. Kan afvige betydeligt: All of the approvals in the RTOR pilot have come ahead of the applications’ user fee dates, with approval times ranging from 11 days to five months after submission.
-
Full dosier submission for Maia var 12. marts. Der er masser af tid endnu.https://www.focr.org/news/pink-sheet-real-time-oncology-review-has-sponsors-rethinking-what-data-share-us-fda-and-when
-
Undrer mig over denne dato information
Sektioner
Forside
Medicinal & Biotek
Medico & Rehab
Digital sundhed
Samfund
English
Log ind
Genmab-partner søger om europæisk godkendelse af Darzalex-kombinationAF KEVIN GRØNNEMANN
Offentliggjort 22.03.19 kl. 11:54
Biotekselskabet Genmabs salgspartner Janssen har fredag insendt en ansøgning til EMA, som skal få kræftmidlet Darzalex godkendt i kombination med to andre midler. -
Umiddelbart lyder det jo underligt, at der skulle være en synergieffekt mellem NKTR-255 og dara, da 255 aktiverer NK-celler og dara har det med gerne at ville slå NK-celler ihjel (de udtrykker CD38). Men måske netop derfor? Et spm, der nok snarere skulle stilles til Winkel, når vi snart ser ham igen.
-
"a news conference by Janssen Korea to celebrate the drug’s winning insurance benefit on Thursday." http://www.koreabiomed.com/news/articleView.html?idxno=5598
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind